World’s First Phase III Clinical Trial of COVID-19 Inactivated Vaccine Begins in UAE
The first WHO enlisted global clinical Phase III trial of Sinopharm CNBG’s inactivated vaccine to combat COVID-19 has started in Abu Dhabi, inspired by the UAE Leadership’s commitment to overcome the pandemic through a global collaborative effort.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200717005085/en/
H.E. Sheikh Abdullah bin Mohammed Al Hamed, Chairman of Department of Health, Abu Dhabi, being administered the world’s first clinical Phase III trial of inactivated vaccine to combat COVID-19 (Photo - AETOSWire).
H.E. Sheikh Abdullah bin Mohammed Al Hamed, Chairman of the Department of Health, Abu Dhabi, was the first in the world to commence the trial of a Phase III inactivated vaccine for COVID-19 that is the result of a cooperation partnership between Abu Dhabi based G42 Healthcare and Sinopharm CNBG, the world’s sixth largest vaccine manufacturer.
The UAE was selected to conduct the trials as the nation is home to over 200 nationalities, allowing for robust research across multiple ethnicities and increasing its feasibility for global application. They are being operated by Abu Dhabi Health Services (SEHA) who are providing clinical facilities.
UAE Health Authorities have issued a permit for up to 15,000 volunteers to participate and G42 Healthcare and SEHA are working towards achieving a minimum of 5,000 participants for the trials being supervised by the Department of Health Abu Dhabi and SEHA following international guidelines stipulated by WHO and USFDA.
Chairperson of the UAE National COVID-19 Clinical Management Committee Dr. Nawal Ahmed Alkaabi said: “Our participation in this trial enables us to make a major contribution in the global fight to combat the COVID-19 pandemic. We are proud to facilitate the testing process that if successful leads to the manufacture of a vaccine.”
It follows successful phase I and II trials by Sinopharm in China, resulting in 100% of volunteers generating antibodies.
G42 Healthcare CEO Ashish Koshy said: “We are enormously proud to partner with Sinopharm CNBG in this groundbreaking phase III clinical trial. Using our AI solutions, super-computer, advanced diagnostics solutions for COVID-19, and G42 Healthcare will be responsible for running clinical operations for these trials.”
Jingjin Zhu, President, Biological products, Sinopharm CNBG added: “The UAE is a nation of innovation and tolerance, home to individuals from every part of the world and ethnic background. We will work closely with our partner G42 Healthcare, with the support of the Abu Dhabi health authorities to complete these clinical trials successfully and make this vaccine available to people in need worldwide.”
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aptorum Group Launches Infectious Disease Liquid Biopsy Subsidiary Start-up and Exclusively In-licensed from Singapore based Accelerate Technologies To Co-Develop Molecular Based Rapid Pathogen Diagnostics Technology To Track Pathogenic Genome29.9.2020 12:00:00 CEST | Press release
Regulatory News: Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) ) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases, announced its launch of Aptorum Innovations - an infectious disease liquid biopsy diagnostics subsidiary and its newly established exclusive in-licensing arrangements with Accelerate Technologies Pte Ltd (“Accelerate Technologies”), commercialization arm of the Singapore’s Agency for Science, Technology and Research (“A*STAR”), to co-develop novel molecular-based rapid pathogen identification and detection diagnostics (“RPIDD”) technology. Aptorum Innovations, intends to target the global molecular diagnostics market estimated to reach USD$13.8billion in market size by 2025, of which 60% is estimated to be attributable to the infectious disease segment1, with its next-generation RPIDD technology. The RPIDD technology was initiated and currently under development at A*STAR. Th
Jellagen ® Ltd Announces Collaboration With Mayo Clinic29.9.2020 11:35:00 CEST | Press release
Jellagen® Limited, a marine biotechnology business manufacturing high value collagen derived from jellyfish, has entered into a license agreement for an exclusive grant to patent rights with Mayo Clinic for the development in treatment of vocal cord paralysis. Vocal cord paralysis [VCP] is an injury to one or both recurrent laryngeal nerves (RLNs), which control most of the muscles of the larynx. This results in paralysis of the vocal cord muscles which can lead to airways obstruction, dyspnea, altered voice etc. VCP is caused by surgery side effects, trauma, tumors, etc. It is also frequent in the vocal cords of “heavy users” population such as singers, actors, politicians and teachers. The worldwide VCP market is estimated at $2.6B in 2020 with the bulk injection market segment accounting for 15% with 4% CAGR over the next five years, i.e $380M in 2020. Thomas-Paul Descamps, Chief Executive Officer, commented, “We are very proud to have signed this agreement with Mayo Clinic and is t
Open Banking: Partnership between Ebury and Nexi29.9.2020 11:30:00 CEST | Press release
Nexi, the leading Italian PayTech in digital payments, signs a partnership with Ebury, one of the world's leading Fintech companies providing global transaction banking services to businesses. According to the agreement, Ebury, founded in 2009 and with offices in 20 countries including Italy, joins Nexi Open. Nexi's partner banks will be able to offer their clients the full suite of Ebury services, including international cash management, FX risk management and import/export lending. Credit institutions will be able to expand their global transaction services with innovative solutions to overcome some of the traditional complexities of cross-border transactions. For example, Ebury International Cash Management services allow customers to open multi-currency accounts in a few hours; FX Risk Management services help businesses to reduce the risks associated with international trade; the single platform for cross-border payments gives customers a simple and transparent way to pay supplier
Boehringer Ingelheim invests to further develop the pet care market in China29.9.2020 10:00:00 CEST | Press release
Boehringer Ingelheim has acquired an equity stake in China-based New Ruipeng Group (NRP Group). NRP Group is a fast-growing business that offers veterinary care, e-commerce and many other services to pet owners and the broader animal health market across China. “Improving the health of animals and humans is what drives us in Boehringer Ingelheim. Strong collaborations and partnerships have always been key to achieving this goal,” commented Jean Scheftsik de Szolnok, Member of the Board of Managing Directors with responsibility for Animal Health. “Together with NRP Group and other partners we are looking forward to serving pet owners in China and contributing with our knowledge in areas such as disease understanding or training and education.” China’s pet market is one of the fastest growing markets in the world. The number of pets is continuously rising as they play an increasingly significant role in people’s lives, and pet owners are looking for integrated online and offline products
GLEIF Defines new Validation Agent Role for Banks & Financial Institutions to Simplify and Accelerate Client Lifecycle Management29.9.2020 09:55:00 CEST | Press release
The Global Legal Entity Identifier Foundation (GLEIF) has today announced that financial institutions (FIs) worldwide can realize a variety of cost, efficiency and customer experience benefits by assuming a new ‘Validation Agent’ role within the Global LEI System. FIs acting as Validation Agents simplify LEI issuance for their clients, reduce time-to-revenue, and future proof their institutions for digital innovation. The Validation Agent Framework is a new operational model in the Global LEI System. By leveraging their know-your-customer (KYC), anti-money laundering (AML) and other regulated ‘business-as-usual’ onboarding processes, Validation Agents can now obtain an LEI for their customers when verifying a client’s identity during initial onboarding or during a standard client refresh update. Until now, labor intensive and time consuming legal document and data collection procedures, which are conducted as standard to verify the identity of a client entity within a bank’s onboarding
ADVA delivers unprecedented precision in timing networks with TrueTime™29.9.2020 09:00:00 CEST | Press release
ADVA (FSE: ADV) today announced a new and robust way to deliver unprecedented levels of precision in timing networks. Built on ADVA’s TrueTime™ technology, this new end-to-end solution will prove key for 5G, smart grid and other time-sensitive applications. Unlike other delivery mechanisms, TrueTime™ uses PTP-optimized optical transport to provide accurate synchronization from the core of the network all the way to the edge. It does this by combining ePRTC core clocks and ultra-precise boundary clocks to ensure nanosecond timing. Not only does this method provide PRTC levels of accuracy, but it’s also more robust than any competing solution and this is key in the battle to mitigate the risk of GNSS vulnerabilities. What’s more, in greenfield deployments, TrueTime™ enables service providers to reduce the number of PRTC core clocks and GNSS equipment, simplifying network management and reducing costs. This press release features multimedia. View the full release here: https://www.busines
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom